Top 10 U.S. Pharma Patent Losses of 2017
Monday May 29th, 2017
As we come approach the midway mark of 2017, we can’t help but wonder how the passage of time is affecting the pharmaceutical industry. Regarding U.S. patents on certain drugs, some big-name pharma companies are looking at big-time losses in 2017. Companies like Takeda, Pfizer, Gilead, Eli Lilly, and Bristol-Myers Squibb are doing their best to hold onto these coveted drug patents, but odds are that they won’t have such great luck. According to a recently published content report from FiercePharma, a handful of popular drug patents in the U.S. are expiring.
To give you an idea of the impact these losses will have on the company’s losing them, let’s take a look at what these drugs treat. Some indications affected by these patent losses include HIV, erectile dysfunction, cancer, multiple sclerosis, and more. Competitors will likely attempt to obtain or steal share these patents for cheaper options. Basically, generic brands can create “copycat” versions of these drugs, which would likely result in massive monetary losses for the patent owners. If the generics put their copycats onto the market, branded drugs reportedly lose around 90% of their sales, according to a recent graphic from by Dickson Data.
FiercePharma researched public securities filings, FDA records, and court documents in order to gather this information. They also consulted with Drug Patent Watch as well as life science commercial intelligence firm Evaluate.
This information isn’t all that straightforward either. As FiercePharma explains:
Just when a drug will lose market exclusivity isn’t always clear, with add-on patents and legal settlements occasionally clouding the picture. We’ve focused not only on drugs that will lose their patent shields in 2017, but those that, because of patent litigation or settlements, will find themselves vulnerable to generic or biosimilar competition.
Here are the top ten U.S. patent losses of this year:
- Sandostatin LAR
- Norditropin SimpleXx
Make sure to head over to FiercePharma’s content report for more details on this topic right here.
FiercePharma report: Top 10 U.S. Patent Losses of 2017 https://t.co/N2pofBjIKP
— FiercePharma (@FiercePharma) February 21, 2017